The Latest Breaking News from Paul Burton

Vaccination developer Moderna is calling for action on the current jab programme warning people could find themselves 'under-protected and under-vaccinated'

US biotech firm agrees £1bn deal with government for centre to combat Covid and other illnesses

It comes as Moderna announced that its variant vaccine can create a strong antibody response to the BA.4 and the BA.5 variants.

The biotech company's experimental Omicron booster generates high levels of antibodies that neutralise subvariants BA.4 and BA.5, according to preliminary clinical trial data.

Moderna shot is said to produce eightfold increase in antibody levels against Omicron in first four weeks

People who received vaccine showed significant jump in antibody levels compared to original Moderna jab

Moderna Inc. said its COVID-19 vaccine that targets omicron generated a “superior” immune response against the variant compared to its original shot in a widely awaited study that could pave the way for another round of boosters in the fall.

Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.…

Stock futures nudge higher ahead of Fed meeting, jobs data; Week Ahead: Fed meeting, earnings, jobs data in focus; Warren Buffett details first quarter spending spree, wins key votes; Activision shares leap as Buffett reveals 9.5% stake and Moderna shares edge higher on under 6 vaccine approval hopes

Children ages 6 months to under 6 years may soon have access to a Covid-19 vaccine that has been submitted to the FDA for emergency use authorization.

Moderna Inc. applied for emergency use authorization for its COVID-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus.